



The Veterinary Biologics Industry Response to Emerging Disease


Hans A. Draayer

1st International One Health Congress

February 14-16



Melbourne, Australia

Industry Dilemma - Where to begin?




“Emerging” Scenario Considerations


- What is “Emerging”
 - Geographic Expansion – *West Nile*, *Rift Valley Fever*, *FMD*
 - Strain variance, re-assortant – *c-H3N8*, *a-H5N1*, *pH1N1 Influenza*
 - New entity (identified or “emerged”) – *CPV*, *PRRS*, *PCV*
- Species Consideration
 - Livestock
 - Companion Animal
 - Zoonotic potential
- Regulatory Considerations
 - Fast track approach availability
 - Regional control strategies
 - Stockpile plans
- Other Factors
 - Availability of technology
 - Intellectual property, Freedom to Operate
 - Severity, potential economic impact
 - Rate of spread



Animal Health Biological Pathway and Timeline



Timeline



2-5 Years

Timeline not to scale



Scenario 1: Pandemic H1N1

- What is “Emerging”
 - Re-assortant – pH1N1 Influenza ✓
- Species Consideration
 - Livestock (swine)/Zoonotic ✓
- Regulatory Considerations
 - USDA Master Seed and Conditional license option ✓
- Other Factors
 - Availability of technology, Pfizer’s Influenza platform ✓
 - Intellectual property, Freedom to Operate ✓
 - Severity, potential economic impact ✓
 - Rate of spread ✓



pH1N1 Timeline


- April 2009: Novel influenza A (H1N1) Isolated in Mexico and the United States Rapid Spread of Virus in Humans Throughout the World
- June 2009: Cases of Novel Influenza A (H1N1) reported in over 70 Countries. World Health Organization elevates the Worldwide Pandemic Alert Level to Phase 6
- June 2009 USDA VS Memorandum No. 09-10: Availability of H1N1 Influenza Virus
- Aug, 2009: Pfizer Receipt of USDA Master Seeds
- December 2009 – Conditional USDA license issued and product made available
- September 2010: Full USDA license issued

Impact on timelines – pH1N1

New Vaccine




pH1N1 – Response in under emergency conditions



Rift Valley Fever

- Mosquito vectored viral disease – Africa
 - US mosquitoes are compatible vectors – similar to West Nile
 - Predominantly in cattle, sheep, and goats
- Epidemics occur when vertebrates that develop high viremia are present
 - Arthropod, direct and aerosol transmission from blood documented
 - Established epidemics in new territory: Egypt, Saudi, Yemen
- Potential for intentional spread

West Nile Example





Scenario 2: Rift Valley Fever


- What is “Emerging”
 - Geographic Expansion – Rift Valley Fever
- Species Consideration
 - Livestock (cattle/sheep)/Zoonotic ✓
- Regulatory Considerations
 - Pathway defined
 - US Conditional license option ✓
 - Stockpile potential
- Other Factors
 - Technology is available ✓
 - Freedom to Operate ✓
 - Severity, potential economic impact ✓
 - Rate of spread
- Missing
 - Drivers to accelerate a risk based or high technology program

Impact on timelines – RVF

New Vaccine



RVF – non emergency, exotic pathogen timeline





Key Learning's

- Industry will use a risk based development process driven by public perception, actual need and financial considerations
- “Plug and Play” production and testing systems are critical to rapid response
- Open and frequent dialog with regulatory agency coupled with agreed on development plans are critical for a rapid response
- Pfizer and USDA have demonstrated the industry can respond rapidly in an emergency situation
- Rapid response requires an appropriate risk analysis based approach by both industry and government